<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Phencyclidine (PCP) intoxication in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Phencyclidine (PCP) intoxication in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Phencyclidine (PCP) intoxication in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kennon Heard, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jason Hoppe, DO
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Stolbach, MD, MPH, FAACT, FACMT, FACEP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 20, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite a fall in popularity since the 1970s, phencyclidine (PCP) continues to be used. Approximately 500 exposure cases involving PCP are reported to United States poison centers annually and that number appears to be stable [
         <a href="#rid1">
          1
         </a>
         ]. Early identification and prompt symptomatic treatment are vital to avoid possible sequelae, including rhabdomyolysis and seizures.
        </p>
        <p>
         The basic pharmacology, clinical manifestations, and management of PCP intoxication in adults is reviewed here. The management of PCP poisoning in children,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         and other sympathomimetic poisonings, and other issues related to the management of the poisoned patient are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6506.html" rel="external">
          "Phencyclidine (PCP) intoxication in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/298.html" rel="external">
          "Ketamine poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PHARMACOLOGY AND CELLULAR TOXICOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         PCP, or 1-(1-phenylcyclohexyl) piperidine hydrochloride, is a synthetic arylcycloalkylamine discovered in 1926 and a dissociative anesthetic. It is synthesized from piperidine and cyclohexanone [
         <a href="#rid2">
          2
         </a>
         ]. It is a weak base with a pKa of 8.6 and is soluble in water and ethanol [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         PCP is a stable white solid with a bitter taste. It is manufactured in many forms for recreational use, including powder, crystal, liquid, and tablets [
         <a href="#rid4">
          4
         </a>
         ]. It has been sprinkled on leaves for ingestion, and there are reports of it being combined with embalming fluid to enable the drug's uniform distribution in cigarettes (often referred to as "wet," "illy," or "fry") [
         <a href="#rid5">
          5
         </a>
         ]. Concentrations of the drug vary in PCP tablets (1 to 6 mg) and PCP-laced marijuana (1 to 10 mg) [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         PCP has a number of analogs that may also be abused, including PHP (rolicyclidine, phenylcyclohexylpyrrolidine), PCE (N-ethyl-1-phenylcyclohexylamine), TCP (1-[1-(2-thienyl) cyclohexyl] piperidine), and PCC (1-piperidinocyclohexane-carbonitrile). PCC is commonly found in street grade PCP. PCC has the potential for increased toxicity due to the release of hydrogen cyanide when smoked [
         <a href="#rid2">
          2
         </a>
         ], although acute cyanide toxicity is unlikely [
         <a href="#rid8">
          8
         </a>
         ]. Another analog 3-Methoxyphencyclidine appears to cause similar effects [
         <a href="#rid9">
          9
         </a>
         ] and has been implicated in several deaths [
         <a href="#rid10">
          10-12
         </a>
         ]. There have been reports of less well-regulated designer drugs related to PCP with similar toxicity profiles including: methoxphenidine (a diarylethylamine) [
         <a href="#rid13">
          13
         </a>
         ], and gacyclidine (a derivative of PCP or TCP) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         The dose of PCP varies depending upon the amount of active drug and the route. In general, symptoms first appear at 0.05 mg/kg. Alteration of body image has been reported at 0.1 mg/kg and 10 mg has been reported to cause catatonic stupor [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         PCP is a noncompetitive antagonist of NMDA receptors [
         <a href="#rid16">
          16
         </a>
         ]. It also stimulates sigma receptors and blocks the reuptake of biogenic amines. Stimulation of alpha adrenergic receptors is thought to be responsible for its sympathomimetic effects and cerebral vasospasm.
        </p>
        <p>
         PCP has three primary sites of action in the central nervous system:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         N-methyl-D-aspartate (NMDA) receptor complex – PCP has great affinity for NMDA receptor complexes in the hippocampus, neocortex, basal ganglia, and limbic system [
         <a href="#rid16">
          16
         </a>
         ]. NMDA antagonism at these sites produces acute psychosis that mimics schizophrenia in humans and leads to excess excitatory neurotransmitter release (eg, glutamate, glycine, aspartate) that can cause agitation and seizures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          Dopamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         , and serotonin reuptake complex – PCP inhibits reuptake of dopamine, norepinephrine, and serotonin in neurons [
         <a href="#rid17">
          17
         </a>
         ]. This action contributes to the adrenergic and dopaminergic effects of PCP intoxication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sigma receptor complex – PCP binding to the sigma receptor may explain, in part, the psychotic, anticholinergic, and movement abnormalities seen with intoxication [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          KINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The absorption, peak serum concentration, and duration of effect vary with the route of PCP use. A retrospective study of 1000 patients found smoking to be the most common route (72 percent), usually via laced cigarettes or marijuana, followed by insufflation (13 percent), ingestion (12 percent), and intravenous (IV) injection (1.5 percent) [
         <a href="#rid6">
          6
         </a>
         ]. Smoking, insufflation, and IV or intramuscular routes produce symptoms within two to five minutes, while oral ingestion produces symptoms in 30 to 60 minutes.
        </p>
        <p>
         Smoking causes a rapid initial peak in plasma concentrations at five minutes and a second peak at 22 minutes. The second peak may be related to delayed absorption from the lungs. The mean half-life after smoking (24 hours) is similar to the IV route [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         The peak effect following ingestion is approximately 90 minutes. The duration of action (one to three hours) is similar to the IV route [
         <a href="#rid19">
          19
         </a>
         ]. PCP may undergo enterogastric recycling following oral doses [
         <a href="#rid20">
          20
         </a>
         ]. Although not well absorbed in the stomach, PCP is actively secreted into the gastric fluid, where concentrations can reach 50 times that of the serum. It is then absorbed in the more alkaline small intestines.
        </p>
        <p>
         IV injection of PCP produces an immediate effect. Following IV injection, the duration of action is one to two hours, despite the long terminal half-life (21 hours).
        </p>
        <p>
         PCP has a large volume of distribution (6.2 L/kg) and is 65 percent protein bound [
         <a href="#rid19">
          19
         </a>
         ]. The drug's high lipid solubility accounts for the ease with which it crosses the blood brain barrier and enters adipose tissue [
         <a href="#rid16">
          16
         </a>
         ]. Cerebrospinal fluid (CSF) levels are reported to be four times serum levels due to the slightly more acidic pH of the CSF [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         PCP displays first order kinetics with a half-life of 7 to 26 hours [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Elimination of PCP is principally by hepatic metabolism [
         <a href="#rid19">
          19
         </a>
         ]. It is rapidly metabolized in the liver to hydroxylated derivatives and excreted in the urine primarily as a mono-4-hydroxypiperidine conjugate. These metabolites are thought to have minimal pharmacologic activity [
         <a href="#rid3">
          3
         </a>
         ]. Approximately 5 to 10 percent is excreted unchanged in the urine [
         <a href="#rid20">
          20
         </a>
         ]. A lower urine pH increases renal clearance, but this contributes little to overall elimination and may be dangerous. (See
         <a class="local">
          'Enhanced elimination'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES OF OVERDOSE
         </span>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of PCP intoxication is made based upon the history and clinical evaluation. Unfortunately, a clear history is often unavailable as patients are frequently alone and exhibit alterations in mental status. Sometimes friends or emergency medical services personnel provide useful details. It can be helpful to know the street names for PCP, which include angel dust, embalming fluid, killer weed, peace pill, horse tranquilizer, and hog [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
         Severe poisoning can occur if a patient ingests large amounts of poorly packaged drug to avoid discovery by the authorities (body stuffing) or a break occurs in a container of concentrated drug that the patient has swallowed for the purpose of illicit transport (body packing). Co-ingestants are common with PCP use and may alter the clinical presentation or treatment. Marijuana cigarettes sometimes contain PCP [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/327.html" rel="external">
          "Internal concealment of drugs of abuse (body packing)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Physical examination
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          General findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Physical examination should begin with an assessment of the patient's airway, breathing, circulation, and mental status. Although uncommon, patients with large PCP ingestions may present with profound CNS and respiratory depression requiring immediate endotracheal intubation. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p>
         PCP intoxication can produce a wide range of vital signs and physical findings depending upon the amount ingested, the route of administration, patient susceptibility, and the presence of co-ingestants (in one case series, 54 percent took another substance) [
         <a href="#rid25">
          25
         </a>
         ]. Adrenergic stimulation is typical, but patients may exhibit central nervous system (CNS) stimulation or depression. Most patients are alert but experience hallucinations and demonstrate odd behavior and agitation similar to acute psychosis [
         <a href="#rid6">
          6
         </a>
         ]. Patients may unexpectedly progress to coma, which may be prolonged. Because of this unpredictability, vital signs and clinical assessment should be repeated often until the patient has stabilized.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Vital signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood pressure elevation is reported in 32 to 57 percent of patients with PCP intoxication. Systolic blood pressure correlates with elevated plasma drug concentrations and is significantly higher than controls [
         <a href="#rid26">
          26,27
         </a>
         ]. According to a large retrospective case series, hypertension resolves in less than four hours in 62 percent of cases but persists over 24 hours in 11 percent [
         <a href="#rid6">
          6
         </a>
         ]. Spontaneous intracranial hemorrhage in association with uncontrolled hypertension has been reported [
         <a href="#rid28">
          28-30
         </a>
         ].
        </p>
        <p>
         Tachycardia occurs in 30 to 43 percent of patients with a positive urine PCP test [
         <a href="#rid6">
          6,26
         </a>
         ]. In a case control study, tachycardia was more common in patients with confirmed PCP intoxication [
         <a href="#rid27">
          27
         </a>
         ]. Patients may be hyperthermic (2.6 to 4 percent) or hypothermic (6.4 percent) depending upon the degree of psychomotor agitation and environmental conditions [
         <a href="#rid6">
          6,31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Neuropsychiatric findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         CNS signs and symptoms are common and vary widely. Patients may be alert with bizarre behavior, agitated or violent, or sedated and bordering on comatose. Furthermore, these symptoms may wax and wane over time. In case series, 46 to 52 percent of patients were alert and oriented upon arrival to the hospital, but most are alert and awake [
         <a href="#rid6">
          6,25
         </a>
         ].
        </p>
        <p>
         Psychomotor agitation occurs often, with observational data suggesting a rate between 34 and 64 percent [
         <a href="#rid6">
          6,26
         </a>
         ]. Violence has been reported in 13 to 35 percent of patients and is more common in single drug exposures. According to a case series of 1000 confirmed PCP-intoxicated patients, 13 percent were involved in an altercation, of which 33 percent involved a gun or knife used to threaten others and 22 percent involved self-inflicted wounds [
         <a href="#rid6">
          6
         </a>
         ]. Such violent behavior may be associated with delusions of super-human strength and diminished pain perception. Caregivers should be cautious when caring for agitated patients with possible PCP intoxication.
        </p>
        <p>
         In the same case series, psychomotor symptoms related to PCP intoxication were grouped into major and minor patterns [
         <a href="#rid6">
          6
         </a>
         ]. Major symptoms, including acute brain syndrome (defined below), psychosis, catatonia, and coma, were associated with a more severe course and poorer outcomes. Complications included trauma (16 percent of patients), rhabdomyolysis (2.2 percent), and aspiration pneumonia (1 percent). Minor symptoms included lethargy or stupor and combinations of bizarre behavior, violence, agitation, and euphoria in patients who were otherwise alert and oriented. Minor symptoms were usually associated with a less severe clinical course.
        </p>
        <p>
         Acute brain syndrome, defined as disorientation combined with confusion, lack of judgment, inappropriate affect, or loss of memory, was the most common major symptom, reported in 37 percent of patients in one case series [
         <a href="#rid32">
          32
         </a>
         ]. Psychosis was reported in 16.6 percent of patients in the aforementioned series, including 63 percent of patients without co-ingestants. A smaller case series reported a high rate of auditory hallucinations [
         <a href="#rid31">
          31
         </a>
         ]. Visual and tactile hallucinations can also occur. Full recovery from psychosis may take weeks to months [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         In the case series cited above, catatonia was found in 11.7 percent of patients [
         <a href="#rid32">
          32
         </a>
         ]. In another series, approximately 6 percent of patients were reported to be wandering in public and 56 percent of them had disrobed [
         <a href="#rid6">
          6
         </a>
         ]. Catatonia is typically of short duration with 85 percent of cases resolving by 24 hours [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Lethargy or stupor was reported in 3.8 percent of patients [
         <a href="#rid32">
          32
         </a>
         ]. Coma was reported in 11 percent of patients, with the duration of unconsciousness ranging from 30 minutes to seven days. A smaller case series reported that 50 percent of patients developed a decreased level of consciousness at some time during their clinical course [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Horizontal, vertical, or rotatory nystagmus is common with reported rates ranging from 57 to 89 percent of cases (
         <a class="graphic graphic_table graphicRef74834" href="/z/d/graphic/74834.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid6">
          6,27
         </a>
         ]. Other potential CNS effects include dystonic reactions, tardive dyskinesia, and athetosis, but these are rare. Symptoms such as ataxia, dysarthria, nausea, and vomiting may also occur.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fatalities in the setting of PCP intoxication are uncommon and most are secondary to trauma. Other causes include hyperthermia, respiratory arrest, and intracranial hemorrhage.
        </p>
        <p>
         Treating clinicians should be aware of the potential for multiple serious complications in patients with PCP intoxication. These occur most often with large ingestions and may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rhabdomyolysis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypoglycemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolonged comatose state
        </p>
        <p>
        </p>
        <p>
         Rhabdomyolysis developed in 2.2 percent of patients in one series of 1000 patients [
         <a href="#rid32">
          32
         </a>
         ] and hemodialysis was necessary in 0.3 percent. In another case series, 40 percent of patients with PCP-associated rhabdomyolysis (defined as myoglobinuria and a creatine phosphokinase concentration above 16,000 IU/L) developed acute renal failure [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Seizures occur infrequently, with estimates ranging from 2.6 to 6 percent of cases [
         <a href="#rid6">
          6,31,36
         </a>
         ]. Status epilepticus has been reported.
        </p>
        <p>
         Prolonged psychiatric illness may stem from an underlying condition or drug effect. Psychiatric evaluation should be obtained after a period of observation confirms the patient is medically stable. A retrospective review performed at a psychiatric facility found that 20 patients with new-onset PCP-induced psychosis needed shorter hospitalizations (average 4.8 days; range 1 to 9) compared with 20 patients with new-onset functional psychosis (13.9 days; range 3 to 41) [
         <a href="#rid37">
          37
         </a>
         ]. However, there are reports of patients with PCP-induced psychosis requiring up to four to six weeks for full recovery.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to the variable presentation of PCP intoxication, the differential diagnosis is considerable. Other toxicologic causes that should be entertained in cases of altered mental status, hallucinations, and excessive adrenergic activity include sympathomimetics, anticholinergic toxicity, other hallucinogens (LSD, mescaline, and psilocybin), ethanol or sedative hypnotic drug withdrawal, neuroleptic malignant syndrome (NMS), serotonin syndrome, and salicylate toxicity (
         <a class="graphic graphic_table graphicRef59893" href="/z/d/graphic/59893.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/289.html" rel="external">
          "Evaluation of abnormal behavior in the emergency department"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/311.html" rel="external">
          "Methamphetamine: Acute intoxication"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/317.html" rel="external">
          "Intoxication from LSD and other common hallucinogens"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/329.html" rel="external">
          "Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"
         </a>
         .)
        </p>
        <p>
         Medical illness must also be considered. Altered mental status and vital sign abnormalities should lead to careful evaluation for central nervous system infections (encephalitis, meningitis) and sepsis. Metabolic etiologies such as hypoglycemia, hyponatremia, hyperthyroidism, and hypoxia are easily assessed and should be investigated. Occult head trauma can cause acute changes in mental status. Patients without apparent medical or toxicologic illness who remain symptomatic should be evaluated for possible psychosis. (See
         <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">
          "Clinical features and diagnosis of acute bacterial meningitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">
          "Diagnosis of delirium and confusional states"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          LABORATORY EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          General testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine laboratory evaluation of the poisoned patient should include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An electrocardiogram, to assess for cardiac conduction abnormalities
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          Acetaminophen
         </a>
         and salicylate concentrations (in patients with suspected self-harm ingestion), to rule out these common co-ingestions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy test in women of childbearing age
        </p>
        <p>
        </p>
        <p>
         Several other laboratory studies are indicated in the setting of PCP intoxication, including creatine kinase, urine myoglobin, and liver transaminases. Further testing is performed based upon clinical assessment. As examples, BUN and creatinine are obtained if rhabdomyolysis or other potential causes of renal failure are suspected, while a CT of the head and evaluation of cerebrospinal fluid may be needed in the setting of a persistently altered mental status.
        </p>
        <p>
         The most common laboratory abnormalities associated with PCP intoxication include an elevated creatine kinase (70 percent), elevated liver transaminases (50 percent), hyperuricemia (24 percent), and hypoglycemia (22 percent) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Testing for PCP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum and urine tests to determine PCP concentrations are available at some hospitals. However, the results of such tests are generally not available with sufficient speed to be of use during acute management.
        </p>
        <p>
         Serum concentrations were once widely available, but with the decreased prevalence of PCP, most labs offer qualitative testing only. Qualitative testing is more helpful than quantitative concentrations since serum levels do not correlate well with brain concentrations or clinical toxicity [
         <a href="#rid26">
          26,27
         </a>
         ]. Confirmatory testing using gas chromatography with mass spectroscopy is performed on rare occasions when definitive drug identification is needed [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         The United States National Institute on Drug Abuse (NIDA) guidelines for federal workplace drug testing uses a cutoff urine PCP concentration of 25 ng/mL. Urine toxicology screens may remain positive for several weeks. In one series of chronic users, urine screens remained positive for an average of 14 days [
         <a href="#rid39">
          39
         </a>
         ]. CSF testing has been reported in two cases with concentrations one to four times the serum levels [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Multiple causes of false positive urine tests have been reported and the potential adverse medicolegal consequences of such results are profound. Drugs capable of causing a false positive urine test include
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         [
         <a href="#rid40">
          40
         </a>
         ],
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         [
         <a href="#rid38">
          38,41
         </a>
         ],
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         [
         <a href="#rid42">
          42
         </a>
         ],
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ], and
         <a class="drug drug_general" data-topicid="10010" href="/z/d/drug information/10010.html" rel="external">
          tramadol
         </a>
         [
         <a href="#rid44">
          44,45
         </a>
         ]. In addition, there is evidence to suggest that
         <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">
          alprazolam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          carvedilol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         may cross react as well [
         <a href="#rid46">
          46,47
         </a>
         ]. Because the cross-reactivity of tests varies among manufacturers, the best information is available from the test manual.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Airway, breathing, and circulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial stabilization including a rapid assessment of the airway, breathing, and circulation is important. Airway protection with endotracheal intubation and mechanical ventilation was necessary in 1.2 percent of patients in one large case series [
         <a href="#rid32">
          32
         </a>
         ]. Theoretically,
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         may exacerbate rhabdomyolysis-related hyperkalemia.
        </p>
        <p>
         Some clinicians believe that PCP intoxication may increase airway secretions and the risk of laryngospasm, but such cases are likely to be extremely uncommon.
        </p>
        <p>
         Patients with potentially life-threatening clinical findings (eg, stupor, hyperthermia) are placed on a cardiac monitor, given supplemental oxygen, and have intravenous access established. Abnormal vital signs are addressed immediately, and advanced life support measures are instituted as needed. Further acute interventions are based upon clinical findings, as quantitative testing for PCP is generally unavailable and unhelpful. (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Sedation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rapid control of psychomotor agitation is the cornerstone of successful management. Physical restraints may be necessary initially and several staff members are often needed to control patients agitated from PCP. Thereafter, chemical sedation is essential to control agitation, prevent or treat hyperthermia, perform a thorough physical examination, and obtain necessary studies.
        </p>
        <p>
         Little evidence exists to guide the use of sedatives in the management of PCP intoxication. Based upon observational reports and broad clinical experience, we believe benzodiazepines are the preferred agents to achieve chemical sedation. We treat severely agitated patients immediately with benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         4 mg intravenously [IV] or
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         5 mg IV, or intramuscularly [IM] if IV access is not available). These doses can be repeated every five to ten minutes based upon patient response.
        </p>
        <p>
         Butyrophenones (eg,
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         5 mg or
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         5 to 10 mg) may be used as adjunctive therapy when benzodiazepines do not adequately control symptoms [
         <a href="#rid48">
          48
         </a>
         ]. These doses may be repeated. Some clinicians prefer to avoid butyrophenones because they are purported to lower the seizure threshold and impair heat dissipation in hyperthermic patients. However, there are no high-quality studies in humans to support such claims.
        </p>
        <p>
         In the rare case of severe refractory psychomotor agitation or status epilepticus, treatment with a barbiturate or a
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         infusion may be necessary. Endotracheal intubation and mechanical ventilation are commonly required in such instances.
        </p>
        <p>
         We treat mildly or moderately intoxicated patients with benzodiazepines and a quiet environment.
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          Lorazepam
         </a>
         1 to 2 mg IV or
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         2 to 5 mg IV may be adequate, and should be repeated as needed. Small observational studies suggest that sensory deprivation (dark, quiet room; hands covered) may decrease agitation [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Treatment of complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once adequate sedation is achieved, the patient with PCP intoxication should be carefully examined for secondary injuries. PCP intoxication often leads to bizarre behavior, hallucinations, delusions of physical prowess, and a diminished perception of pain. As a result, PCP abuse is often associated with trauma. A large case series reported injuries in 13 percent of patients, 22 percent of which were self-inflicted [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Other major potential complications of PCP intoxication include hyperthermia, seizures, rhabdomyolysis, and hypertension. Hyperthermia typically improves with adequate sedation, but external cooling and, in a small number of severe refractory cases, even paralysis and mechanical ventilation may be necessary. Hypertension is typically transient and rarely requires pharmacologic intervention beyond sedation. Refractory hypertension can be treated with short acting agents such as
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         or
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         that can be titrated to effect. Cardiac monitoring and frequent reexamination are essential in patients with any significant complication. (See
         <a class="medical medical_review" href="/z/d/html/176.html" rel="external">
          "Severe nonexertional hyperthermia (classic heat stroke) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2217.html" rel="external">
          "Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3837.html" rel="external">
          "Evaluation and treatment of hypertensive emergencies in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">
          "Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"
         </a>
         .)
        </p>
        <p>
         Animal studies suggest that antipsychotic medications can block PCP mediated behavioral effects [
         <a href="#rid50">
          50
         </a>
         ]. Clinical trials in humans are needed before this approach can be recommended.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients survive PCP intoxication uneventfully with supportive care; decontamination is generally unnecessary in isolated ingestions. However, decontamination with activated charcoal (AC) may be useful if a massive ingestion or a potentially dangerous co-ingestant is present and treatment is started within one hour of ingestion. Patients who ingest large amounts of PCP to avoid police detection (body stuffers) or to transport drug for distribution (body packers) may sustain massive ingestions. Any potential benefit from AC must be weighed against the risk of aspiration, especially given the potential for altered mental status and seizures with severe PCP intoxication. AC is given in a dose of 1 g/kg (maximum 50 g).
        </p>
        <p>
         We do NOT typically use multidose activated charcoal (MDAC) in patients with PCP intoxication. MDAC provides a theoretical benefit because of the extensive enterohepatic recirculation of PCP. Dogs treated with AC following oral doses of PCP demonstrated decreased duration of anesthesia, seizures, and death [
         <a href="#rid51">
          51
         </a>
         ]. Giving rats activated charcoal following an oral dose of PCP significantly elevated the lethal dose (LD50) of PCP [
         <a href="#rid51">
          51
         </a>
         ]. However, there is no evidence of clinical benefit in humans, and the potential for aspiration exists whenever AC is given.
        </p>
        <p>
         We do
         <strong>
          not
         </strong>
         suggest the use of nasogastric suction in patients with PCP intoxication. Nasogastric suction is theoretically beneficial when performed soon after ingestion due to the high concentration of PCP in the stomach's acidic environment. However, it has no proven benefit and may cause electrolyte abnormalities, aspiration, and unwanted difficulty in agitated patients.
        </p>
        <p>
         Whole bowel irrigation is
         <strong>
          not
         </strong>
         routinely recommended. It should only be used in patients who have ingested potentially lethal amounts of PCP, as may occur with body stuffers or body packers. (See
         <a class="medical medical_review" href="/z/d/html/327.html" rel="external">
          "Internal concealment of drugs of abuse (body packing)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Enhanced elimination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neither urine acidification nor charcoal hemoperfusion should be used in the treatment of PCP intoxication.
        </p>
        <p>
         Although some toxicologists have proposed urinary acidification as a means of increasing PCP clearance [
         <a href="#rid20">
          20
         </a>
         ], this process increases total drug clearance by only one percent [
         <a href="#rid4">
          4,7
         </a>
         ]. Moreover, acidification increases the potential for systemic acidosis, worsening rhabdomyolysis and renal damage, and precipitation of uric acid leading to nephrolithiasis [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         In a study of dogs loaded with 5 mg/kg of PCP, charcoal hemoperfusion failed to reduce the number of seizures, duration of coma, or tissue concentration compared with control animals [
         <a href="#rid53">
          53
         </a>
         ]. Only 2 percent of the parent compound was recovered. The authors concluded that PCP's high volume of distribution, high lipid solubility, and low plasma concentration make removal by hemoperfusion ineffective.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          DISPOSITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to the variable course of PCP toxicity, even patients without severe symptoms or complications benefit from some period of observation. Patients presenting early following an ingestion may be asymptomatic initially but should be observed for at least six hours. Patients with mild symptoms presenting a few hours after the onset of intoxication generally recover within several hours. Such patients may be discharged provided the effects of intoxication have resolved and the patient remains symptom-free during a brief (one to two hours) period of observation. In a case series of 184 patients, 83 percent went home, 8 percent were admitted, and the rest were transferred to a crisis center [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Any patient with significant complications (eg, rhabdomyolysis, coma, status epilepticus) or severe symptoms (eg, uncontrolled hypertension, hyperthermia) should be admitted to an intensive care setting. Patients with less severe but persistent symptoms should be admitted to an appropriate ward for further monitoring and treatment.
        </p>
        <p>
         Psychiatric evaluation should be obtained where appropriate, once medical problems have been addressed. Chronic abusers may benefit from treatment for substance abuse. (See
         <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">
          "Substance use disorders: Clinical assessment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          FUTURE CONSIDERATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supportive care remains the cornerstone of the management of PCP toxicity. However, the use of monoclonal antibodies to reverse toxicity is being studied and may provide an alternative approach in the future [
         <a href="#rid54">
          54,55
         </a>
         ]. Monoclonal anti-phencyclidine Fab antibody fragments successfully reversed PCP-induced locomotor effects in a rat model [
         <a href="#rid54">
          54
         </a>
         ]. These antibodies are not able to cross the blood brain barrier and directly reverse receptor binding. However, the antibodies decrease the concentration of free PCP and alter its pharmacokinetics.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          PEDIATRIC CONSIDERATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical presentation of PCP intoxication is different in infants and young children than in adolescents or adults. The diagnosis and management of children with PCP intoxication is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6506.html" rel="external">
          "Phencyclidine (PCP) intoxication in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H89018971">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H1950582039">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1975171301">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">
          "Society guideline links: General measures for acute poisoning treatment"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114015.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by recreational drug or alcohol use"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacology and kinetics
         </strong>
         – Phencyclidine (PCP) is a dissociative anesthetic that is abused primarily for its hallucinatory effects. Significant toxicity is rare but potentially serious. The drug's onset of action is rapid, but the duration of action is generally brief (one to four hours). (See
         <a class="local">
          'Pharmacology and cellular toxicology'
         </a>
         above and
         <a class="local">
          'Kinetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Symptoms and signs of PCP intoxication vary depending upon the route of exposure, dose, and co-ingestants, and may include altered mental status (from comatose to profound psychomotor agitation), hallucinations, hypertension, tachycardia, and multidirectional nystagmus. Severe complications may include traumatic injuries, rhabdomyolysis, hyperthermia, and seizures. (See
         <a class="local">
          'Clinical features of overdose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Due to the variable presentation of PCP intoxication, the differential diagnosis is vast. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory testing for PCP
         </strong>
         – Quantitative drug concentrations have little role in the management of acute toxicity. Qualitative testing is available, but false positives are frequent. Results may remain positive for weeks. (See
         <a class="local">
          'Testing for PCP'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Control of agitation
         </strong>
         – Rapid control of psychomotor agitation is the cornerstone of successful management. Physical restraints may be necessary initially and several staff members are often needed to control patients agitated from PCP. Chemical sedation should be administered as rapidly as possible. Decontamination and other aspects of management are discussed above. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with PCP-related psychomotor agitation who require sedation, we suggest the use of benzodiazepines (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We treat severely agitated patients immediately with intravenous (IV) benzodiazepines (
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         4 mg IV or
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         5 to 10 mg IV). These doses can be repeated every eight to ten minutes based upon patient response. In severely intoxicated patients, intramuscular (IM) injection may be used initially if IV access is unavailable.
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          Midazolam
         </a>
         (5 mg IM) may be used in such situations. (See
         <a class="local">
          'Sedation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We treat mildly or moderately intoxicated patients with benzodiazepines and a quiet environment.
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          Lorazepam
         </a>
         1 to 2 mg IV or
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         2 to 5 mg IV may be adequate, and may be repeated as needed. (See
         <a class="local">
          'Sedation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disposition
         </strong>
         – Patients with significant symptoms should be admitted to a monitored setting. Due to the relatively short duration of action, patients with mild symptoms are candidates for a period of observation and discharge. Patients whose medical symptoms resolve but have persistent behavioral issues should undergo a psychiatric evaluation. (See
         <a class="local">
          'Disposition'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shesser R, Jotte R, Olshaker J. The contribution of impurities to the acute morbidity of illegal drug use. Am J Emerg Med 1991; 9:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liden CB, Lovejoy FH Jr, Costello CE. Phencyclidine. Nine cases of poisoning. JAMA 1975; 234:513.
          </a>
         </li>
         <li class="breakAll">
          Pali MJ, Tharratt RS, Albertson TE. Phencyclidine and its congeners. In: Critical Care Toxicology, 1st ed, Brent J, Wallace KL, Burkhart KK, et al (Eds), Mosby, Philadelphia 2005. p.777.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland JA, Nelson L, Ravikumar PR, Elwood WN. Embalming fluid-soaked marijuana: new high or new guise for PCP? J Psychoactive Drugs 1998; 30:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarron MM, Schulze BW, Thompson GA, et al. Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med 1981; 10:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook CE, Brine DR, Jeffcoat AR, et al. Phencyclidine disposition after intravenous and oral doses. Clin Pharmacol Ther 1982; 31:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tschirgi T. Phencyclidine: A hidden risk of illicit drug use. Pharm Alert 1990; 19:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bäckberg M, Beck O, Helander A. Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clin Toxicol (Phila) 2015; 53:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell-Mata C, Thomas B, Peterson B, Couper F. Two Fatal Intoxications Involving 3-Methoxyphencyclidine. J Anal Toxicol 2017; 41:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zidkova M, Hlozek T, Balik M, et al. Two Cases of Non-fatal Intoxication with a Novel Street Hallucinogen: 3-Methoxy-Phencyclidine. J Anal Toxicol 2017; 41:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakota E, Arndt C, Romoser AA, Wilson SK. Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method. J Anal Toxicol 2016; 40:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofer KE, Degrandi C, Müller DM, et al. Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine. Clin Toxicol (Phila) 2014; 52:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chenoweth JA, Gerona RR, Ford JB, et al. Altered mental status and end organ damage associated with the use of gacyclidine: a case series. J Med Toxicol 2015; 11:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aniline O, Pitts FN Jr. Phencyclidine (PCP): a review and perspectives. Crit Rev Toxicol 1982; 10:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akunne HC, Reid AA, Thurkauf A, et al. [3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex. Synapse 1991; 8:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe SA Jr, De Souza EB. Sigma and phencyclidine receptors in the brain-endocrine-immune axis. NIDA Res Monogr 1993; 133:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook CE, Brine DR, Quin GD, et al. Phencyclidine and phenylcyclohexene disposition after smoking phencyclidine. Clin Pharmacol Ther 1982; 31:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aronow R, Done AK. Phencyclidine overdose: an emerging concept of management. JACEP 1978; 7:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donaldson JO, Baselt RC. CSF phencyclidine. Am J Psychiatry 1979; 136:1341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson JE. Phencyclidine pharmacokinetics after a massive overdose. Ann Intern Med 1989; 111:613.
          </a>
         </li>
         <li class="breakAll">
          Caravatti EM. Hallucinogenic drugs. In: Medical Toxicology, 3rd ed, Dart RC, Caravatti EM, McGuigan MA, et al (Eds), Lippincott, Williams, and Wilkins, Philadelphia 2004. p.1106.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milhorn HT Jr. Diagnosis and management of phencyclidine intoxication. Am Fam Physician 1991; 43:1293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dominici P, Kopec K, Manur R, et al. Phencyclidine Intoxication Case Series Study. J Med Toxicol 2015; 11:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailey DN. Phencyclidine abuse. Clinical findings and concentrations in biological fluids after nonfatal intoxication. Am J Clin Pathol 1979; 72:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barton CH, Sterling ML, Vaziri ND. Phencyclidine intoxication: clinical experience in 27 cases confirmed by urine assay. Ann Emerg Med 1981; 10:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bessen HA. Intracranial hemorrhage associated with phencyclidine abuse. JAMA 1982; 248:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eastman JW, Cohen SN. Hypertensive crisis and death associated with phencyclidine poisoning. JAMA 1975; 231:1270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crosley CJ, Binet EF. Cerebrovascular complications in phencyclidine intoxication. J Pediatr 1979; 94:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yago KB, Pitts FN Jr, Burgoyne RW, et al. The urban epidemic of phencyclidine (PCP) use: clinical and laboratory evidence from a public psychiatric hospital emergency service. J Clin Psychiatry 1981; 42:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarron MM, Schulze BW, Thompson GA, et al. Acute phencyclidine intoxication: clinical patterns, complications, and treatment. Ann Emerg Med 1981; 10:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright HH, Cole EA, Batey SR, Hanna K. Phencyclidine-induced psychosis: eight-year follow-up of ten cases. South Med J 1988; 81:565.
          </a>
         </li>
         <li class="breakAll">
          Pali MJ, Tharratt RS, Albertson TE. Phencyclidine and its congeners. In: Critical Care Toxicology, 1st ed, Brent J, Wallace KL, Burkhart KK, et al (Eds), Mosby, Philadelphia 2005. p.777.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akmal M, Valdin JR, McCarron MM, Massry SG. Rhabdomyolysis with and without acute renal failure in patients with phencyclidine intoxication. Am J Nephrol 1981; 1:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kessler GF Jr, Demers LM, Berlin C, Brennan RW. Letter: Phencyclidine and fatal status epilepticus. N Engl J Med 1974; 291:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carls KA, Ruehter VL. An evaluation of phencyclidine (PCP) psychosis: a retrospective analysis at a state facility. Am J Drug Alcohol Abuse 2006; 32:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Budai B, Iskandar H. Dextromethorphan can produce false positive phencyclidine testing with HPLC. Am J Emerg Med 2002; 20:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson GM, Khajawall AM, Alatorre E, Staples FR. Urinary phencyclidine excretion in chronic abusers. J Toxicol Clin Toxicol 1982; 19:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman RJ, Saddock V, Nelson L. Effect of ketamine on phencyclidine immunoassays (abstract). J Toxicol Clin Toxicol 2001; 39:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schier J. Avoid unfavorable consequences: dextromethorpan can bring about a false-positive phencyclidine urine drug screen. J Emerg Med 2000; 18:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine BS, Smith ML. Effects of diphenhydramine on immunoassays of phencyclidine in urine. Clin Chem 1990; 36:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos PM, López-García P, Navarro JS, et al. False positive phencyclidine results caused by venlafaxine. Am J Psychiatry 2007; 164:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull MJ, Griggs D, Knoepp SM, et al. Postmortem urine immunoassay showing false-positive phencyclidine reactivity in a case of fatal tramadol overdose. Am J Forensic Med Pathol 2006; 27:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ly BT, Thornton SL, Buono C, et al. False-positive urine phencyclidine immunoassay screen result caused by interference by tramadol and its metabolites. Ann Emerg Med 2012; 59:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rengarajan A, Mullins ME. How often do false-positive phencyclidine urine screens occur with use of common medications? Clin Toxicol (Phila) 2013; 51:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geraci MJ, Peele J, McCoy SL, Elias B. Phencyclidine false positive induced by lamotrigine (Lamictal®) on a rapid urine toxicology screen. Int J Emerg Med 2010; 3:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannini AJ, Nageotte C, Loiselle RH, et al. Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity. J Toxicol Clin Toxicol 1984-1985; 22:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           COHEN BD, LUBY ED, ROSENBAUM G, GOTTLIEB JS. Combined sernyl and sensory deprivation. Compr Psychiatry 1960; 1:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grayson B, Idris NF, Neill JC. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 2007; 184:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picchioni AL, Consroe PF. Activated charcoal--a phencyclidine antidote, or hog in dogs. N Engl J Med 1979; 300:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barton CH, Sterling ML, Vaziri ND. Rhabdomyolysis and acute renal failure associated with phencyclidine intoxication. Arch Intern Med 1980; 140:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen WR, O'Barr TP, Corby DG. Hemoperfusion of phencyclidine in the dog. Int J Artif Organs 1985; 8:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardin JS, Wessinger WD, Proksch JW, Owens SM. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. J Pharmacol Exp Ther 1998; 285:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacy HM, Gunnell MG, Laurenzana EM, Owens SM. Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. Int Immunopharmacol 2008; 8:1.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 313 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2054004" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The contribution of impurities to the acute morbidity of illegal drug use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1242171" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Phencyclidine. Nine cases of poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1242171" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Phencyclidine. Nine cases of poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9692385" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Embalming fluid-soaked marijuana: new high or new guise for PCP?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7224271" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7075111" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Phencyclidine disposition after intravenous and oral doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Phencyclidine: A hidden risk of illicit drug use
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26295489" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28830118" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Two Fatal Intoxications Involving 3-Methoxyphencyclidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28158698" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Two Cases of Non-fatal Intoxication with a Novel Street Hallucinogen: 3-Methoxy-Phencyclidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27339479" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25350467" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25048606" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Altered mental status and end organ damage associated with the use of gacyclidine: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7044685" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Phencyclidine (PCP): a review and perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1654746" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Recent advances in the phencyclidine model of schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1833849" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : [3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8232518" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sigma and phencyclidine receptors in the brain-endocrine-immune axis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7075112" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Phencyclidine and phenylcyclohexene disposition after smoking phencyclidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/628122" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Phencyclidine overdose: an emerging concept of management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/484738" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : CSF phencyclidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2774390" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Phencyclidine pharmacokinetics after a massive overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2774390" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Phencyclidine pharmacokinetics after a massive overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2008817" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Diagnosis and management of phencyclidine intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25502414" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Phencyclidine Intoxication Case Series Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/506993" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Phencyclidine abuse. Clinical findings and concentrations in biological fluids after nonfatal intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7224272" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Phencyclidine intoxication: clinical experience in 27 cases confirmed by urine assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7097906" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Intracranial hemorrhage associated with phencyclidine abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1172955" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hypertensive crisis and death associated with phencyclidine poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/762634" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cerebrovascular complications in phencyclidine intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7217023" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The urban epidemic of phencyclidine (PCP) use: clinical and laboratory evidence from a public psychiatric hospital emergency service.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7235337" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Acute phencyclidine intoxication: clinical patterns, complications, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3368805" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Phencyclidine-induced psychosis: eight-year follow-up of ten cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3368805" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Phencyclidine-induced psychosis: eight-year follow-up of ten cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7349047" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Rhabdomyolysis with and without acute renal failure in patients with phencyclidine intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4414337" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Letter: Phencyclidine and fatal status epilepticus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17127556" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : An evaluation of phencyclidine (PCP) psychosis: a retrospective analysis at a state facility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11781921" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Dextromethorphan can produce false positive phencyclidine testing with HPLC.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7184997" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Urinary phencyclidine excretion in chronic abusers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effect of ketamine on phencyclidine immunoassays (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10787303" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Avoid unfavorable consequences: dextromethorpan can bring about a false-positive phencyclidine urine drug screen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2357810" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effects of diphenhydramine on immunoassays of phencyclidine in urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17267806" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : False positive phencyclidine results caused by venlafaxine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17133040" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Postmortem urine immunoassay showing false-positive phencyclidine reactivity in a case of fatal tramadol overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21924518" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : False-positive urine phencyclidine immunoassay screen result caused by interference by tramadol and its metabolites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23697457" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : How often do false-positive phencyclidine urine screens occur with use of common medications?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21373301" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Phencyclidine false positive induced by lamotrigine (Lamictal®) on a rapid urine toxicology screen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6535849" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13694346" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Combined sernyl and sensory deprivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17675172" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/759857" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Activated charcoal--a phencyclidine antidote, or hog in dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7362395" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Rhabdomyolysis and acute renal failure associated with phencyclidine intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3988362" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Hemoperfusion of phencyclidine in the dog.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9618414" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18068094" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
